Documents
Application Sponsors
BLA 761158 | GLAXOSMITHKLINE | |
Marketing Status
Application Products
001 | INJECTABLE;INTRAVENOUS | 2.5MG/KG | 0 | BLENREP | BELANTAMAB MAFODOTIN-BLMF |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2020-08-05 | PRIORITY |
REMS; REMS | SUPPL | 3 | AP | 2020-11-20 | N/A |
LABELING; Labeling | SUPPL | 6 | AP | 2022-02-28 | STANDARD |
REMS; REMS | SUPPL | 7 | AP | 2021-12-07 | N/A |
Submissions Property Types
ORIG | 1 | Null | 7 |
SUPPL | 3 | Null | 15 |
SUPPL | 6 | Null | 6 |
SUPPL | 7 | Null | 15 |
CDER Filings
GLAXOSMITHKLINE
cder:Array
(
[0] => Array
(
[ApplNo] => 761158
[companyName] => GLAXOSMITHKLINE
[docInserts] => ["Medication Guide","https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf#page=21"]
[products] => [{"drugName":"BLENREP","activeIngredients":"BELANTAMAB MAFODOTIN-BLMF","strength":"2.5MG\/KG","dosageForm":"INJECTABLE;INTRAVENOUS","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"08\/05\/2020","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/761158s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"08\/05\/2020","submission":"ORIG-1","actionType":"Approval","submissionClassification":"","reviewPriority":"N\/A; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/761158s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/761158Orig1s000ltr.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2020-08-05
)
)